A phase 1/2 study of ALT-803 in patients with relapse/re

Project: Research project

Project Details

Description

A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
StatusActive
Effective start/end date6/1/155/31/21

Funding

  • ALTOR BIOSCIENCE LLC

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.